# psoriasis - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 5409
- Completion tokens: 6388
- Reasoning tokens: 
- Total tokens: 11797
- API requests reported: 
- Elapsed seconds: 18.098
- Final benchmark system: raw; file rank 4/5; original repeat 5; model vendor: Google Gemini

---
Based on the transcriptomic comparison between psoriatic lesional skin and normal control skin, here is a multidimensional, evidence-grounded biological interpretation of the provided statistical output.

---

### 1. Overall Biological Interpretation

The input differential expression profile captures the classic pathophysiological hallmarks of **psoriasis vulgaris** at the tissue level. The transcriptome of psoriatic lesional skin is dominated by profound **upregulation of inflammatory cytokine networks, antimicrobial peptides (AMPs), cornification/epidermal differentiation machinery, and metabolic reprogramming**, alongside down-regulation of homeostatic skin signaling mediators (e.g., *BTC*).

Rather than isolated single-gene alterations, the data show coordinated activation across three major interconnected axes:
1. **The Epithelial–Immune Inflammatory Loop:** Strong induction of interleukin-36 family members (*IL36A*, *IL36G*), IL-20 family cytokines (*IL19*, *IL20*), and downstream response elements (*TNIP3*, *IRAK2*).
2. **Aberrant Keratinocyte Differentiation & Barrier Remodeling:** Widespread upregulation of small proline-rich proteins (*SPRR2A*, *SPRR2B*, *SPRR2D*, *SPRR3*, *SPRR2F*, *SPRR2G*), late cornified envelope proteins (*LCE3A*, *LCE3D*), gap junction proteins (*GJB2*, *GJB6*), and serine protease inhibitors (*PI3*, *SERPINB3*, *SERPINB4*).
3. **Innate Host Defense & Chemotaxis:** Massive fold changes in defensins (*DEFB4A*, *DEFB4B*, *DEFB103A/B*), S100 alarmins (*S100A7*, *S100A8*, *S100A12*), and leukocyte chemoattractants (*CXCL13*, *CXCR2*, *GPR15LG*).

Concurrently, metabolic adaptations in keratinocytes and immune infiltrates are marked by elevated tryptophan metabolism (*KYNU*), lipid binding/processing (*FABP5*, *PLA2G4D*, *PLA2G4E*), and aldo-keto reductases (*AKR1B10*, *AKR1B15*). Downregulation of *BTC* (Betacellulin) suggests altered epidermal growth factor signaling homeostasis amid marked epidermal hyperplasia.

---

### 2. Core Biological Programs

#### Program 1: IL-36 / IL-23 / IL-17 Axis Inflammatory Signaling
* **Direction:** Strongly Upregulated
* **Major Supporting Genes:** *IL36A* ($\text{log}_2\text{FC} = 11.37$), *IL36G* ($5.68$), *IL19* ($7.58$), *IL20* ($5.67$), *IL26* ($4.36$), *TNIP3* ($7.28$), *IRAK2* ($2.08$), *IL36RN* ($3.01$).
* **Standardized Pathway:** Reactome: *Interleukin-36 signaling* (R-HSA-9020591) / KEGG: *Cytokine-cytokine receptor interaction* (hsa04060).
* **Biological Rationale:** *IL36A* and *IL36G* are key driver cytokines in psoriatic inflammation, produced by keratinocytes and dendritic cells. They feed into an autocrine loop that drives NF-$\kappa$B and AP-1 activation via *IRAK2*, leading to expression of downstream IL-20 family members (*IL19*, *IL20*) which stimulate keratinocyte proliferation. *TNIP3* (TNFAIP3-interacting protein 3) and *IL36RN* are concurrently upregulated as endogenous negative feedback regulators attempting to restrain excessive NF-$\kappa$B/IL-1 signaling.
* **Evidence Strength & Limitations:** **Strong evidence.** High effect sizes ($\text{log}_2\text{FC} > 5\text{--}11$) across multiple independent cytokine and feedback genes. A limitation is that bulk RNA-seq cannot resolve whether cytokine production originates primarily from suprabasal keratinocytes or infiltrating myeloid cells.

#### Program 2: Cornified Envelope Formation & Epidermal Hyperkeratosis
* **Direction:** Strongly Upregulated
* **Major Supporting Genes:** *SPRR2A* ($7.31$), *SPRR2B* ($6.38$), *SPRR2D* ($5.92$), *SPRR3* ($7.18$), *LCE3A* ($8.30$), *LCE3D* ($5.31$), *PI3* ($9.24$), *SERPINB3* ($6.74$), *SERPINB4* ($9.12$), *KRT6A* ($4.30$).
* **Standardized Pathway:** GO BP: *Keratinization* (GO:0031424) / Reactome: *Formation of the cornified envelope* (R-HSA-6809371).
* **Biological Rationale:** Epidermal hyperproliferation and altered differentiation in psoriasis lead to an incomplete cornification process. *SPRR* and *LCE* family proteins serve as structural components cross-linked into the cornified envelope. Serine protease inhibitors (*PI3* / Peptidase Inhibitor 3, *SERPINB3*, *SERPINB4*) protect the altered barrier from endogenous and neutrophil-derived proteolytic degradation. *KRT6A* reflects stressed, hyperproliferative keratinocytes.
* **Evidence Strength & Limitations:** **Strong evidence.** Co-induction of structurally related gene clusters located in the Epidermal Differentiation Complex (EDC) on chromosome 1q21. A limitation is that high expression in bulk tissue reflects both individual cellular upregulation and increased overall keratinocyte cell fraction due to acanthosis.

#### Program 3: Innate Antimicrobial Defense & Alarmin Release
* **Direction:** Strongly Upregulated
* **Major Supporting Genes:** *DEFB4A* ($11.18$), *DEFB4B* ($11.03$), *DEFB103A* ($5.76$), *DEFB103B* ($5.75$), *S100A7* ($7.09$), *S100A7A* ($9.83$), *S100A8* ($7.73$), *S100A12* ($8.33$), *TCN1* ($8.04$).
* **Standardized Pathway:** GO BP: *Antimicrobial humoral response* (GO:0019730) / KEGG: *IL-17 signaling pathway* (hsa04657).
* **Biological Rationale:** Antimicrobial peptides (AMPs) are hallmark products of STAT3- and NF-$\kappa$B-driven downstream pathways activated by IL-17A, IL-22, and IL-36. Beta-defensins (*DEFB4A/B*, *DEFB103A/B*) and S100 proteins (*S100A7*, *S100A8*, *S100A12*) act as direct microbicides and endogenous alarmins (DAMPs), amplifying immune activation by chemoattracting neutrophils and activating toll-like receptors (TLRs).
* **Evidence Strength & Limitations:** **Strong evidence.** Extremely high log2FC values ($\text{log}_2\text{FC} > 7\text{--}11$) with robust FDR significance. A limitation is high sequence homology among gene paralogs (e.g., *DEFB4A* vs *DEFB4B*), which can lead to alignment cross-talk in short-read RNA sequencing.

#### Program 4: Keratinocyte Metabolic Reprogramming & Xenobiotic/Lipid Metabolism
* **Direction:** Upregulated
* **Major Supporting Genes:** *KYNU* ($4.42$), *AKR1B10* ($6.27$), *AKR1B15* ($5.23$), *FABP5* ($3.64$), *PLA2G4D* ($4.61$), *VNN3P* ($8.28$), *GDA* ($5.90$).
* **Standardized Pathway:** KEGG: *Tryptophan metabolism* (hsa0380) / Reactome: *Metabolism of lipids* (R-HSA-556833).
* **Biological Rationale:** Psoriatic skin undergoes significant metabolic rewiring. *KYNU* (Kynureninase) processes tryptophan downstream of IDO1/TDO2, generating immunosuppressive or pro-inflammatory metabolites. *FABP5* (Fatty Acid Binding Protein 5) and *PLA2G4D* (Phospholipase A2 Group IVD) regulate eicosanoid and lipid mediator synthesis crucial for epidermal signaling. *AKR1B10* and *AKR1B15* detoxify lipid peroxidation products generated by oxidative stress. *VNN3P* (Vnn3 pseudogene/transcript) and *GDA* (Guanine Deaminase) indicate altered purine and pantetheine catabolism.
* **Evidence Strength & Limitations:** **Moderate to Strong evidence.** Consistent directional change across multiple enzyme categories. Limitations include potential functional divergence or non-coding roles for pseudogene transcripts like *VNN3P*.

#### Program 5: Leukocyte Chemotaxis & Cell-Cell Communication
* **Direction:** Mixed / Predominantly Upregulated
* **Major Supporting Genes:** *CXCL13* ($5.89$), *CXCR2* ($2.70$), *GPR15LG* ($5.52$), *CD274* ($3.44$), *BTC* (Downregulated, $-4.30$).
* **Standardized Pathway:** GO BP: *Leukocyte chemotaxis* (GO:0030595) / KEGG: *Chemokine signaling pathway* (hsa04062).
* **Biological Rationale:** Recruitment of immune cells into lesional skin is driven by chemokines and chemoattractants. *CXCL13* drives B-cell and T-follicular helper cell trafficking, while *CXCR2* mediates neutrophil migration. *GPR15LG* (GPR15 ligand / CCFO14) promotes lymphocyte homing to colon and skin epithelia. Concurrently, *CD274* (PD-L1) upregulation reflects adaptive immune counter-regulation, while the suppression of *BTC* (Betacellulin, an EGFR ligand) indicates altered intercellular growth factor communication.
* **Evidence Strength & Limitations:** **Moderate evidence.** Clear chemokine signal, though specific infiltrating cell types require single-cell resolution or immunohistochemistry to confirm ligand-receptor cell pairing.

---

### 3. Key Genes and Interaction Modules

| Gene | Direction ($\text{log}_2\text{FC}$) | FDR | Proposed Role in Core Biological Programs | Interaction Module & Relationship Type |
| :--- | :---: | :---: | :--- | :--- |
| **IL36A** | $+11.37$ | $1.65 \times 10^{-98}$ | Upstream driver of cutaneous inflammation and keratinocyte activation. | **Regulatory Interaction:** Binds IL-36R to activate NF-$\kappa$B, inducing *IL19*, *IL20*, *DEFB4A*, and *S100A7*. |
| **DEFB4A / DEFB4B** | $+11.18$ / $+11.03$ | $< 4 \times 10^{-71}$ | Principal antimicrobial effector and alarmin. | **Co-expression / Pathway Co-membership:** Downstream transcriptional targets of STAT3/NF-$\kappa$B alongside *S100A7/8*. |
| **S100A12** | $+8.33$ | $7.94 \times 10^{-97}$ | Neutrophil-derived alarmin; activates RAGE receptor signaling. | **Pathway Co-membership:** Functional synergy with *S100A8/A9* and *CXCR2* in neutrophil recruitment. |
| **SPRR2A / SPRR3** | $+7.31$ / $+7.18$ | $< 2 \times 10^{-70}$ | Structural cornified envelope precursors in hyperkeratotic epidermis. | **Co-expression / Physical Assembly:** Direct physical integration into the cornified cell envelope via transglutaminase cross-linking. |
| **TNIP3** | $+7.27$ | $2.82 \times 10^{-83}$ | Negative regulator of NF-$\kappa$B signaling (A20-binding inhibitor). | **Regulatory Interaction:** Inhibits TRAF6/NF-$\kappa$B activation downstream of IL-1R/IL-36R; co-expressed as an inducible feedback loop. |
| **SERPINB4** | $+9.12$ | $6.68 \times 10^{-68}$ | Protease inhibitor protecting tissue from cathepsin G / papain-like proteases. | **Co-expression / Regulatory:** Co-regulated by IL-13/IL-4 and IL-17 pathways in differentiated keratinocytes. |
| **KYNU** | $+4.42$ | $2.00 \times 10^{-91}$ | Rate-limiting enzyme in tryptophan-kynurenine pathway. | **Pathway Co-membership:** Works in metabolic cascade downstream of IDO1 to modulate local immune tolerance and inflammation. |
| **GJB2** | $+4.42$ | $1.74 \times 10^{-86}$ | Gap junction beta-2 (Connexin 26); facilitates intercellular epidermal communication. | **Direct Physical Interaction:** Forms hexameric connexon channels interacting with *GJB6* (Connexin 30) in suprabasal keratinocytes. |
| **BTC** | $-4.30$ | $1.78 \times 10^{-73}$ | Epidermal growth factor receptor (EGFR) ligand. | **Regulatory Interaction:** Downregulated during inflammatory keratinocyte stress, shifting EGFR signaling balance. |
| **CD274 (PD-L1)** | $+3.44$ | $1.82 \times 10^{-63}$ | Immune checkpoint ligand expressed on antigen-presenting cells/keratinocytes. | **Regulatory Interaction:** Direct physical contact with PD-1 on T cells to suppress T-cell hyperactivation. |

---

### 4. Validation Priorities

#### 1. IL-36 Signaling Cascade as a Drivers vs. Responders Hierarchy
* **Classification:** Mechanistic hypothesis
* **Prioritization Rationale:** *IL36A* is the most highly upregulated cytokine ($\text{log}_2\text{FC} = 11.37$). Distinguishing whether IL-36 acts upstream of IL-20/IL-19 in primary human keratinocytes will confirm therapeutic hierarchy.
* **Current Data Support:** Concurrent massive upregulation of *IL36A*, *IL36G*, *IL19*, *IL20*, and *TNIP3*.
* **External Evidence:** Loss-of-function mutations in *IL36RN* cause generalized pustular psoriasis (GPP), establishing direct genetic causality for unchecked IL-36 activity.
* **Next Validation Step:** Recombinant IL-36 stimulation of primary human keratinocyte 3D skin models combined with siRNA knockdown of *IL36R* (*IL1RL2*) followed by RNA-seq.
* **Status:** **Supported hypothesis**

#### 2. Kynurenine Pathway Activation (*KYNU*) as a Metabolic Immunomodulator
* **Classification:** Therapeutic target / Biomarker
* **Prioritization Rationale:** Tryptophan catabolism (*KYNU*, $\text{log}_2\text{FC} = 4.42$) links keratinocyte metabolic stress with immune cell modulation, offering potential small-molecule intervention targets.
* **Current Data Support:** Highly significant upregulation ($P = 7.18 \times 10^{-95}$, $\text{FDR} = 2.00 \times 10^{-91}$).
* **External Evidence:** Kynurenine metabolites are elevated in psoriatic serum and correlate with PASI (Psoriasis Area and Severity Index) scores.
* **Next Validation Step:** Targeted LC-MS/MS metabolomics measuring kynurenine pathway intermediates (3-hydroxykynurenine, xanthurenic acid) in skin biopsies and paired plasma.
* **Status:** **Exploratory hypothesis**

#### 3. Connexin Channel Remodeling (*GJB2* / *GJB6*) in Epidermal Architecture
* **Classification:** Interaction / network hypothesis
* **Prioritization Rationale:** High expression of *GJB2* ($4.42$) and *GJB6* ($3.02$) reflects altered intercellular communication in acanthotic epidermis.
* **Current Data Support:** Co-upregulation of both connexin subunits with extreme statistical significance ($\text{FDR} < 10^{-68}$).
* **External Evidence:** *GJB2* mutations cause KID syndrome and palmoplantar keratoderma; Connexin 26 is known to be upregulated in wound healing and psoriatic plaques.
* **Next Validation Step:** Immunofluorescence co-localization and dual-dye transfer assays in patient skin sections to measure gap junction permeability.
* **Status:** **Established evidence**

#### 4. De-orphanization and Functional Assessment of *VNN3P* and Uncharacterized LncRNAs
* **Classification:** Mechanistic hypothesis
* **Prioritization Rationale:** Pseudogenes and lncRNAs (*VNN3P* $\text{log}_2\text{FC} = 8.28$, *LOC107984452* $-6.25$, *WAKMAR1* $-5.63$) show some of the largest fold-changes in the dataset.
* **Current Data Support:** Top-ranked statistical significance ($P = 1.35 \times 10^{-150}$).
* **External Evidence:** Non-coding RNAs (e.g., *WAKMAR1*) have recently been implicated in keratinocyte migration and wound re-epithelialization.
* **Next Validation Step:** qRT-PCR verification, cell-fractionation (nuclear vs. cytoplasmic), and antisense oligonucleotide (ASO) knockdown in human keratinocytes.
* **Status:** **Exploratory hypothesis**

#### 5. Cell-Type Composition Shift vs. Intrinsic Gene Regulation
* **Classification:** Confounding or composition check
* **Prioritization Rationale:** Bulk skin biopsy transcripts reflect both intracellular expression changes and altered cell population ratios (neutrophils, T cells, dendritic cells, hyperplastic keratinocytes).
* **Current Data Support:** Co-detection of leukocyte markers (*CXCR2*, *S100A12*, *CD274*) and keratinocyte structural genes (*SPRR*, *LCE*).
* **External Evidence:** Single-cell RNA-seq (scRNA-seq) of psoriatic skin confirms significant expansion of inflammatory dendritic cells, cytotoxic T cells, and mitotic keratinocytes.
* **Next Validation Step:** Digital cell deconvolution (e.g., CIBERSORTx, BayesPrism) using single-cell reference panels from human skin, coupled with multiplex immunohistochemistry.
* **Status:** **Confounding check required**

---

### 5. Evidence Grounding

```
                     +---------------------------------------+
                     |    Input Differential Expression      |
                     |  Psoriatic Lesion vs. Normal Control  |
                     +-------------------+-------------------+
                                         |
         +-------------------------------+-------------------------------+
         |                               |                               |
         v                               v                               v
+------------------+           +-------------------+           +-------------------+
| Direct Transcript|           | Pathway & Network |           | Literature & Pheno|
| Evidence (Input) |           | Database Annotation|          | Direct Match      |
+--------+---------+           +---------+---------+           +---------+---------+
         |                               |                               |
         | * IL36A (FC 11.37)            | * GO: Keratinization          | * GPP genetics    |
         | * DEFB4A (FC 11.18)           | * KEGG: Cytokine interaction  |   (IL36RN link)   |
         | * S100A12 (FC 8.33)           | * Reactome: Cornified Env.    | * PASI metabolic  |
         | * BTC (FC -4.30)              |                               |   correlates      |
         +-------------------------------+-------------------------------+
```

* **Direct Evidence from Input Dataset:** High magnitude $\text{log}_2\text{FC}$ and low FDR values across cytokine, alarmin, and structural gene clusters establish robust transcriptomic remodeling in lesional tissue.
* **Pathway / Ontology Evidence:** Independent annotations (GO, KEGG, Reactome) converge on keratinization, cytokine receptor signaling, and antimicrobial defense. Note that pathway enrichment relies on underlying shared biological databases (e.g., MSigDB, GO), representing partially overlapping analytical sources.
* **Genetic / Clinical Evidence:** *IL36RN* loss-of-function mutations causing severe pustular psoriasis validate the central pathogenic role of the IL-36 program identified in this dataset.
* **Conflicting Evidence / Knowledge Gaps:** 
  * *TNIP3* and *IL36RN* (inhibitors of inflammation) are strongly upregulated alongside pro-inflammatory cytokines (*IL36A*, *IL19*). This reflects an active, but ultimately insufficient, endogenous counter-regulatory feedback response in lesional tissue.
  * Pseudogenes like *VNN3P* display high fold change ($\text{log}_2\text{FC} = 8.28$), but lack confirmed protein products; non-functional transcript destabilization cannot be ruled out without experimental protein/functional validation (**insufficient evidence for protein activity**).

---

### 6. Limitations and Alternative Explanations

1. **Cell-Composition Bias (Hyperplasia & Infiltration):**
   * *Issue:* Psoriatic skin exhibits epidermal thickening (acanthosis) and dense immune infiltration. High fold changes in keratinocyte-specific (*SPRR*, *LCE*) or neutrophil-specific (*S100A12*, *CXCR2*) genes may reflect changes in cell type proportions within the biopsy core rather than elevated per-cell transcription rates.
   * *Resolution:* Perform single-cell RNA sequencing or spatial transcriptomics combined with cell-type deconvolution algorithms.

2. **Therapeutic and Environmental Exposure Variations:**
   * *Issue:* The input dataset context does not detail systemic or topical treatment histories (e.g., corticosteroids, biologics). Prior treatments can suppress cytokine signals while leaving keratinocyte structural changes intact.
   * *Resolution:* Stratify sample cohorts by treatment status and treatment-naive status.

3. **Co-expression due to Shared Chromosomal Loci (EDC Artifacts):**
   * *Issue:* Genes such as *SPRR2A*, *SPRR2B*, *SPRR2D*, *SPRR3*, *LCE3A*, *LCE3D*, *S100A7*, and *S100A8* reside within the Epidermal Differentiation Complex (EDC) on chromosome 1q21. Co-upregulation may stem from broad chromatin remodeling across the locus rather than independent transcriptional activation events.
   * *Resolution:* Assay chromatin accessibility (ATAC-seq) across chromosome 1q21 to differentiate locus-wide chromatin opening from promoter-specific transcription factor binding.

4. **Association vs. Causation Ambiguity:**
   * *Issue:* Highly upregulated effector genes (e.g., *PI3*, *SERPINB3*, *SERPINB4*) represent downstream tissue responses to inflammation rather than primary drivers of disease onset.
   * *Resolution:* Integrate expression quantitative trait loci (eQTL) data with psoriasis genome-wide association study (GWAS) summary statistics using Mendelian Randomization (MR) to establish causal directions.
